HNPOLY(SZ:300630) Xin Lang Cai Jing·2025-12-23 23:23Group 1 - The core issue revolves around the financial misconduct of Puli Pharmaceutical, which inflated profits by over 669 million yuan over two years, leading to a court ruling in favor of investors seeking compensation for their losses [1][3] - The Haikou Intermediate People's Court has ruled that Puli Pharmaceutical must compensate investors who suffered losses due to false financial reports, with the possibility of an appeal leading to a second trial [1][3] - The company was found to have fabricated sales of finished and raw pharmaceutical products, resulting in a total of 1.031 billion yuan in inflated revenue and 695 million yuan in inflated profits for the years 2021 and 2022, which constituted 31.08% and 76.72% of the reported annual figures, respectively [1][3] Group 2 - Investors who purchased shares between April 26, 2022, and April 16, 2024, and sold or still hold shares after April 17, 2024, are eligible to register for compensation [1][3] - The China Securities Regulatory Commission (CSRC) has stated that it will assist eligible investors in their claims against the company for losses incurred due to financial fraud [2][4] - The focus for investors now shifts to how the court will determine the compensation ratio and whether Puli Pharmaceutical has the financial capacity to pay [2][4]